November 26, 2024 — For the second time this year, we have a meta-analysis of RCTs with GLP-1 medicines that affirms cardiorenal benefits in outcome studies. This latest study appears in Lancet Diabetes and Endocrinology. Lead author Sunil Badve described the importance of his analysis: “This is the first study to show a clear benefit of GLP-1 receptor agonists […]
June 25, 2024 — It’s over. The 84th Scientific Sessions of the American Diabetes Association came to an end yesterday and for anyone interested in obesity, it has given us a lot to absorb. After four days with a steady stream of new information about drugs like the GLP-1 agonists that regulate appetite and adiposity, we are left wondering. […]
June 22, 2024 — We like to celebrate firsts. And yesterday, we got one to celebrate in the first ever drug treatment shown to be effective for sleep apnea – the obesity medicine called tirzepatide. In presenting this new research at the American Diabetes Association Scientific Sessions yesterday, Atul Malhotra reminded us, “sleep is an important part of cardiometabolic […]
April 18, 2024 — Yesterday, Eli Lilly and Company announced topline results for two studies of tirzepatide in people with obesity and sleep apnea. Both in people who were using CPAP devices and in those who were not, the year-long studies yielded results that independent sleep medicine researchers described as “awesome” and “phenomenal.” Clinical scientists will present the details […]
April 6, 2024 — Sleep apnea is a complication of obesity and at the same time, obesity can be a complication of sleep apnea. This two-way relationship sets up a problem that is serious and can be hard to resolve. But it deserves close attention because it can lead to an early death. So, given the tangled relationship between […]
June 30, 2023 — At the ASMBS Annual Meeting this week, a new study of major bad outcomes in people with both obesity and sleep apnea reminds us why metabolic surgery remains an important option for comprehensive obesity care. The risk of death, heart attacks, strokes, and other major bad cardiovascular outcomes is 37 percent lower if a person […]
October 28, 2012 — October 28, 2012 — Look AHEAD, one of the largest obesity outcomes studies funded by NIH, has followed more than 5,000 people for up to eleven years. Half of participants were given intensive lifestyle intervention to lose weight. The other half received general support in the form of diabetes education and doctor visits. Participants in […]
